U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
CARMIEL, Israel, Feb. 22, 2016 -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposiumTM 2016. The details are as follows:
SunTrust Robison Humphrey Orphan Drug Day
February 23, 2016
JW Marriott Essex House, New York City, NY
12th Annual WORLDSymposiumTM 2016
February 29 – March 4, 2016
Manchester Grand Hyatt, San Diego, CA
Oral presentation: “Novel treatment for Fabry disease: IV administration of plant derived alpha-GAL-A enzyme safety and efficacy interim report,” to be presented by Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease. The oral presentation will be given at 3:15 PM PT on Thursday, March 3, 2016.
Poster #138: “PRX-102 α-Galactosidase-A (peguniglasidase alfa) -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease.”
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a pegylated version of a recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-106, an orally-delivered anti-inflammatory treatment; PRX-110, a chemically modified DNase I for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
